New Wave Health Review: What Its GLP-1 Documents Establish—and What They Don’t

A program page can establish that a company markets a treatment. It cannot, by itself, establish how well that company’s patients do. That distinction matters at New Wave Health, which advertises semaglutide, tirzepatide and a lower-dose GLP-1 program alongside provider access and home delivery. Its documentation supplies useful details about the service, but the clinical evidence for a medicine must remain separate from evidence about the particular formulation, prescribing process and follow-up offered through this platform.

This review examines New Wave Health’s public documentation consulted October 19, 2026. The central finding is a mixed one: the company describes a recognizable telehealth pathway and acknowledges important compounded-drug limitations, while leaving several practical questions unresolved. The advertised starting price is not tied to a specific program, cancellation deadlines conflict, and the clinical and pharmacy partners are not named in the consulted materials. Those gaps do not prove poor care; they limit what a reader can verify before enrolling.

At a glance

Business model: New Wave Health LLC describes itself as a technology platform, not the entity providing clinical care, preparing medication or dispensing prescriptions.
Sources: [5]
Documented programs: The site advertises semaglutide, tirzepatide and GLP-1 Microdose; the Microdose page does not unequivocally identify its active ingredient.
Sources: [8] [4] [7]
Advertised starting price: Plans start at $139 per month, confirmed after provider review; the advertised minimum is not linked to a specific medicine or supply quantity.
Sources: [10]
Recurring charges: The terms authorize an immediate charge for a recurring monthly order and subsequent charges every 30 days until cancellation.
Sources: [5]
Conflicting cancellation deadlines: Treatment FAQs require 30 days’ notice, while the terms describe disabling auto-refill at least 48 hours before monthly processing.
Sources: [8] [5]

Start with the entity behind the treatment claims

The terms identify New Wave Health LLC as the owner and operator of mynewwavehealth.com. They also draw a firm boundary around its responsibilities: the company says it connects patients with independent third parties and does not practice medicine, provide clinical care, prepare medication or dispense prescriptions. That distinction is more informative than the general label “GLP-1 provider.” The platform sells access to a coordinated service, but its documents assign clinical judgment and pharmacy work to other organizations.

The website describes access to independent, U.S. board-certified clinical providers and state-licensed compounding pharmacies. Those are the company’s representations, not independently verified credentials in this review. The consulted documents do not identify the individual clinicians, medical groups or dispensing pharmacies by name. Before paying, a useful request is the identity of the treating professional, their actual credential, the medical group responsible for care and the pharmacy expected to fill the prescription.

This is where understanding what provider documents can prove becomes practical. A terms page can document the company’s stated division of responsibility, but it cannot verify a clinician’s license or demonstrate treatment quality. New Wave Health publishes a mailing address at 1832 Kempsville Road, Suite 112, Virginia Beach, Virginia 23464. That gives customers a contact location; it does not establish a walk-in clinic or nationwide clinical availability.

Sources: [5] [10]

Three GLP-1 offerings, with uneven formulation detail

The semaglutide page describes a weekly injection, and its program includes compounded medication. Tirzepatide is presented as a provider-directed dual GLP-1/GIP program with flat-rate pricing. However, the consulted tirzepatide text does not specify its administration route. The Microdose page describes a lower-dose GLP-1 protocol aimed at metabolic health, body composition and appetite recalibration rather than aggressive weight loss, without unequivocally identifying the active ingredient or route. Those missing details matter when comparing an offering with published research.

Microdose is marketed partly to people near their goal weight and people who tolerated standard GLP-1 dosing poorly. Its page excludes people with significant weight to lose whom it considers better served by a standard protocol. These are the provider’s positioning and screening statements, not evidence that the protocol produces metabolic benefits or improves tolerability. The homepage also advertises physician-guided peptide therapies for recovery, metabolism, longevity and focus, described as reviewed by a licensed provider and compounded in a U.S. pharmacy.

New Wave Health says partner U.S. compounding pharmacies prepare its protocols and acknowledges that compounded medications are not FDA approved. FDA recommends compounded drugs when an individual’s medical needs cannot be met by an approved drug, with a prescription and a state-licensed pharmacy. Nonapproval alone does not establish clinical inequivalence, but it also does not establish equivalence. The distinction between approved medicines and compounded preparations should remain visible when evaluating these offerings.

Sources: [8] [4] [7] [10] [1]

Medicine research is not a New Wave Health outcomes report

Research on semaglutide and tirzepatide provides relevant clinical context, but it does not measure New Wave Health’s performance. STEP 1 studied subcutaneous semaglutide in adults with obesity or overweight plus a weight-related condition, without diabetes. SURMOUNT-1 studied subcutaneous tirzepatide in a similar broad population, also excluding diabetes. Neither was a trial of this platform, its partner pharmacies, its compounded preparations or its Microdose protocol. Their findings therefore cannot substantiate a provider-specific success rate.

The same boundary applies to website graphs and testimonials. Even an accurately reproduced trial result does not answer whether the offered preparation, route, patient population and follow-up match the research. A useful approach to separating clinical trials from company performance claims is to ask what was actually studied and who collected the outcomes. The consulted documentation does not establish measured New Wave Health patient results or a published evaluation of its lower-dose protocol.

Safety evidence needs similar care. FDA reports of compounded-drug measurement or administration errors warrant clear instructions from the prescriber or pharmacist; they do not establish an event rate for New Wave Health. Adverse-event reports lack a denominator for calculating a rate and do not automatically establish causation. The practical evidence request is therefore specific: identify the prescribed preparation, explain its instructions and monitoring, and clarify which professional handles medication questions. A review cannot supply patient dosing or substitute for that conversation.

Sources: [7] [8] [2] [3] [1]

From intake to prescribing: what the pathway actually promises

The advertised starting point is an online assessment covering medical history, weight goals and baseline measurements, estimated to take five to ten minutes. Access requires an account with a username and password. Although the homepage says no appointments or clinic visits are needed for intake, the terms still require a consultation before any prescription product can be obtained. A provider must determine that treatment is appropriate and issue a prescription. Completing the form is therefore not a prescription guarantee.

The semaglutide page lists adults 18 or older with a BMI of at least 27, or at least 25 with weight-related conditions, as potential candidates. Those are New Wave Health’s advertised criteria, not a universal prescribing standard. Its BMI calculator is labeled educational, with eligibility left to a licensed provider. The standard-program pages also list exclusions involving personal or family history of medullary thyroid carcinoma or MEN 2, pregnancy, breastfeeding, planned pregnancy, active pancreatitis or untreated severe gastrointestinal disease.

The tirzepatide page additionally markets to people who have plateaued on a single-agonist GLP-1 and want a supervised change. The terms set a general age floor of 18, or the local age of majority if higher. None of these statements settles individual suitability. The consulted materials do not specify laboratory requirements, whether testing is included or how quickly a clinician reviews an intake. Those are important operational questions, distinct from whether a person matches a marketing description.

Sources: [10] [8] [4] [5]

The $139 headline needs a program-specific written quote

New Wave Health advertises “Plans from $139/mo,” confirmed after provider review. The consulted pages do not connect that minimum to semaglutide, tirzepatide, Microdose, a particular formulation or a supply quantity. They also do not establish a later price, introductory period or minimum commitment. This is a real advertised starting price, but not enough information to budget for a specific treatment. No numeric program-by-program price list appears in the consulted materials.

The treatment pages promise pricing review before any charge and no dose-change surcharges. They describe medication, a dedicated provider, direct messaging, structured check-ins and discreet home delivery as part of the flat-rate offering. The terms explain that applicable subscriptions bundle pharmacy charges, medical-group services and platform access. That is useful disclosure of the payment structure, although it does not settle unspecified laboratory costs or establish exactly how much individualized nutrition support is included.

For recurring monthly orders, the terms authorize an immediate charge and charges every 30 days thereafter, with electronic notice five to seven days before a scheduled transaction. That is a 30-day interval, not necessarily the same calendar date each month. The homepage says insurance is not required, but the documentation does not resolve insurance acceptance, reimbursement, prior authorization or HSA/FSA use. Obtain the actual program quote and charge schedule rather than treating the starting figure as a universal price.

What the published commercial terms establish
Item	Documented statement	What still needs confirmation
Starting price	Plans from $139 per month after provider review	Applicable program, formulation and supply quantity
Included services	Medication, provider access, check-ins and home delivery advertised	Laboratory costs and detailed support scope
Recurring payment	Immediate charge, then every 30 days until cancellation	Your amount and actual processing dates
Cancellation	FAQs say 30 days; terms say at least 48 hours before processing	Which deadline governs your enrollment
Refund boundary	Specified services and processed medication are non-refundable	Any remedy before those boundaries are reached

Sources: [10] [8] [5]

Cancellation is documented—but not consistently

The clearest contractual problem is the mismatch between two published cancellation rules. Treatment FAQs say memberships may be canceled with 30 days’ notice before the next billing cycle. The terms instead allow cancellation up to 48 hours before monthly processing by turning off auto-refill in the user portal. The consulted documents do not explain whether these rules apply to different purchases or which controls a particular enrollment. It would be inappropriate to select the more favorable rule on the reader’s behalf.

Request written clarification before authorizing recurring payments, including the applicable deadline, the processing date and how cancellation is confirmed. The electronic renewal notice is not a substitute for that clarification: notice five to seven days before a transaction would arrive too late to satisfy a 30-day requirement for that same transaction. This timing conflict is material even if the clinical service otherwise looks suitable, because it affects whether a patient can avoid the next charge.

Cancellation also does not mean a refund. The treatment FAQs describe consultations, medical visits and fulfilled prescriptions as non-refundable once services begin or medication is processed. That boundary should be distinguished from stopping future renewals. The available terms contain an omitted intermediate section, so this review cannot present the consulted text as a complete account of every contractual provision. The sound conclusion is limited: important cancellation and refund language exists, but the cancellation discrepancy remains unresolved.

Sources: [8] [5]

Pharmacy, shipping and follow-up have separate responsibilities

New Wave Health says an authorized prescription is prepared by a partner compounding pharmacy and shipped directly to the patient. Its terms require accepting the platform’s pharmacy rather than choosing another. Delivery is advertised in temperature-controlled, unmarked packaging, but the consulted documents do not provide preparation, dispatch or arrival timelines, a carrier, or a clear policy for loss or temperature problems. The terms also warn that prescription products will not be dispensed in child-resistant containers.

Nationwide-delivery language on the homepage should not be read as confirmed nationwide clinical service. Treatment pages describe care in Virginia and states where the providers are licensed, without listing all those states. The terms further require patients to be physically in the same state as their account’s shipping address during a consultation. Before enrolling or consulting while traveling, confirm the actual location requirements. A shipping destination and a clinician’s authority to treat a patient are separate questions.

Follow-up is advertised through structured check-ins and direct provider messaging in a secure portal, alongside attention to nutrition, movement, sleep and stress. The frequency of check-ins and clinical-message response time are unspecified. This makes examining follow-up beyond renewal notices particularly useful. For injectable GLP-1 deliveries that arrive warm or insufficiently refrigerated, FDA explicitly advises not using the product and contacting the provider or dispensing pharmacy. Packaging claims do not replace a clear problem-resolution pathway.

Sources: [10] [8] [5] [1]

Privacy and support deserve the same scrutiny as treatment claims

The intake page describes a secure, HIPAA-compliant assessment and encrypted storage. The terms add an important qualification: New Wave Health LLC says it is not a HIPAA covered entity, although it may act as a business associate of a pharmacy or medical group in some circumstances. These statements should be read together. A broad compliance claim does not establish that every piece of information held by the platform receives identical treatment under every part of its service.

The treatment FAQ’s narrower description of sharing with the provider and pharmacy does not capture the full general privacy policy. That policy permits vendors performing payment processing, hosting, marketing, customer support and analytics to access information as needed for their obligations. Its California notice also says some advertising-related disclosures may count as a “sale” or “share” under California law, qualifying the general statement that the company does not sell data. This is a documentation discrepancy, not a legal finding.

For clarification, the contact page lists Dgraves@mynewwavehealth.com and +1 757-573-0882. It publishes clinical hours Monday through Friday, 9 a.m. to 5 p.m., and says contact-form inquiries receive a response within 24 hours. That advertised inquiry response is not a promise of a clinical assessment, prescription decision or delivery within 24 hours. Ask which channel handles billing, clinical concerns and pharmacy problems, particularly outside the published hours.

Sources: [10] [5] [6] [9] [8]

Questions & answers

Does New Wave Health itself prescribe and dispense medication?

Its terms say no: New Wave Health LLC operates the technology platform, while independent providers make clinical decisions and pharmacies prepare and dispense medication. The company advertises access to board-certified clinical providers and state-licensed compounding pharmacies, but the consulted documents do not identify those partners by name. Ask for the treating clinician, medical group and dispensing pharmacy before relying on the platform’s general credential descriptions.

Sources: [5] [10] [8]

Can I get semaglutide or tirzepatide for $139 per month?

The published starting price does not establish that. New Wave Health advertises plans from $139 per month after provider review without assigning that minimum to a specific medicine, formulation or supply quantity. Treatment pages promise review of pricing before charging and no dose-change surcharges. Request a written quote identifying the program, included services, first charge, recurring amount and any separate testing costs.

Sources: [10] [8]

Is the Microdose program supported by the major weight-loss trials?

The consulted evidence does not establish that connection. New Wave Health markets Microdose for metabolic health and body composition, but its page does not unequivocally specify the active ingredient or route. STEP 1 and SURMOUNT-1 did not test this provider’s Microdose protocol. Their results cannot validate its advertised benefits. Ask what exact preparation is offered and what evidence addresses that particular protocol rather than the medication category generally.

Sources: [7] [2] [3]

How much notice do I need to cancel?

The documents conflict. Treatment FAQs require 30 days’ notice before the next billing cycle; the terms describe disabling portal auto-refill at least 48 hours before monthly processing. Do not assume the shorter deadline applies. Obtain written clarification for your purchase and retain cancellation confirmation. Ending future renewals also does not override the stated non-refundable boundaries for services already begun or medication already processed.

Sources: [8] [5]

Can I use my own pharmacy or consult from another state?

The terms require accepting the platform’s pharmacy rather than choosing another. They also require being physically in the same state as the shipping address during the consultation. Treatment pages describe service in Virginia and other states where providers are licensed, without a complete state list. Confirm availability for your actual location; nationwide delivery language does not establish nationwide prescribing access or permission to consult while traveling.

Sources: [5] [8] [10]

Who should I contact about a delivery or medication concern?

The company lists Dgraves@mynewwavehealth.com, +1 757-573-0882 and provider messaging through its patient portal. Ask in advance which contact reaches the dispensing pharmacy and who handles urgent medication questions outside published clinical hours. Its contact-form response claim is not a clinical-response guarantee. If an injectable GLP-1 arrives warm or inadequately refrigerated, FDA advises not using it and contacting the provider or dispensing pharmacy.

Sources: [9] [8] [1]

Our assessment

New Wave Health documents more than a medication advertisement: it describes an intake pathway, independent clinical review, bundled service components, pharmacy fulfillment and ongoing messaging. Its acknowledgment that compounded medications are not FDA approved is also important. However, these disclosures establish the proposed service structure—not provider-specific effectiveness or the benefits of its Microdose protocol. The most consequential unresolved issues are unnamed clinical and pharmacy partners, an unassigned $139 starting price, conflicting cancellation deadlines, incomplete geographic detail and privacy language that varies across pages. A reasonable next step is a written, program-specific explanation covering the preparation, responsible organizations, total charges, monitoring, shipping problems and cancellation rule. Clear answers could make the service easier to evaluate; absent those answers, the public documentation supports only a qualified assessment, not a clinical endorsement.

Visit New Wave Health’s official site ↗

This opens the reviewed business’s website. The link is not a prescription or endorsement. Commercial relationships.

Sources & documentation

Public materials consulted October 19, 2026. Provider statements are attributed claims, not independently verified clinical outcomes. Terms can change; obtain a current written quote.

New Wave Health Review: What Its GLP-1 Documents Establish—and What They Don’t

At a glance

01Start with the entity behind the treatment claims

02Three GLP-1 offerings, with uneven formulation detail

03Medicine research is not a New Wave Health outcomes report

04From intake to prescribing: what the pathway actually promises

05The $139 headline needs a program-specific written quote

06Cancellation is documented—but not consistently

07Pharmacy, shipping and follow-up have separate responsibilities

08Privacy and support deserve the same scrutiny as treatment claims